{
  "meta": {
    "title": "Approach_To_Anemia_-_Part_2",
    "url": "https://brainandscalpel.vercel.app/approach-to-anemia-part-2-1aa46f2a.html",
    "scrapedAt": "2025-11-29T18:24:52.415Z"
  },
  "questions": [
    {
      "id": 20759,
      "choices": [
        {
          "id": 82999,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute chest syndrome </span></span></span></p>"
        },
        {
          "id": 83000,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Stroke </span></span></span></p>"
        },
        {
          "id": 83001,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sepsis </span></span></span></p>"
        },
        {
          "id": 83002,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pulmonary hypertension</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common cause of death in adult patients with sickle cell disease?</span></span></p>",
      "unique_key": "Q8255463",
      "question_audio": null,
      "question_video": null,
      "map_id": 20721,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Acute chest syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute chest syndrome is a leading cause of mortality in adults with SCD, often due to respiratory failure.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Stroke:</span></strong><span style=\"font-size:12.0pt\"> While stroke is a significant cause of morbidity and mortality in children with sickle cell disease (SCD), it is less common in adults.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sepsis:</span></strong><span style=\"font-size:12.0pt\"> Sepsis is a major concern in SCD patients of all ages due to functional asplenia (decreased spleen function). However, acute chest syndrome remains the leading cause of death in adults.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pulmonary hypertension:</span></strong><span style=\"font-size:12.0pt\"> Pulmonary hypertension is a serious complication of SCD, contributing to morbidity and mortality. However, it is not as frequent a cause of death as acute chest syndrome in adults.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Early recognition and aggressive management of acute chest syndrome are crucial in preventing mortality in sickle cell disease.</span></span></span></p>",
      "correct_choice_id": 82999,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20761,
      "choices": [
        {
          "id": 83007,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glutamic acid to lysine </span></span></span></p>"
        },
        {
          "id": 83008,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glutamic acid to valine </span></span></span></p>"
        },
        {
          "id": 83009,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valine to glutamic acid </span></span></span></p>"
        },
        {
          "id": 83010,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lysine to glutamic acid</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The genetic mutation in sickle cell disease results in the substitution of which amino acid in the beta-globin chain?</span></span></p>",
      "unique_key": "Q7941854",
      "question_audio": null,
      "question_video": null,
      "map_id": 20722,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Glutamic acid to valine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The mutation in sickle cell disease is a single nucleotide change (GAG to GTG) in the beta-globin gene, leading to the substitution of glutamic acid with valine at position 6 of the beta-globin chain.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Glutamic acid to lysine:</span></strong><span style=\"font-size:12.0pt\"> This substitution does occur in some hemoglobin variants (e.g., HbC), but not in sickle cell disease (HbS). HbC causes a milder form of anemia compared to HbS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Valine to glutamic acid:</span></strong><span style=\"font-size:12.0pt\"> This would be the reverse of the actual mutation in sickle cell disease and would result in a different hemoglobin variant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Lysine to glutamic acid:</span></strong><span style=\"font-size:12.0pt\"> This substitution is not associated with any known hemoglobinopathy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The specific amino acid substitution (glutamic acid to valine) in sickle cell disease is responsible for the structural and functional abnormalities of hemoglobin S (HbS) that lead to sickling and the associated clinical manifestations.</span></span></span></p>",
      "correct_choice_id": 83008,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20769,
      "choices": [
        {
          "id": 83039,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glutamic acid to lysine </span></span></span></p>"
        },
        {
          "id": 83040,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Valine to glutamic acid </span></span></span></p>"
        },
        {
          "id": 83041,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lysine to glutamic acid </span></span></span></p>"
        },
        {
          "id": 83042,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glutamic acid to valine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old African American woman presents with mild anemia and complains of intermittent abdominal pain. On peripheral blood smear, target cells and rhomboid crystals are noted within red blood cells. Given the likely diagnosis, Which of the following amino acid changes is responsible for this condition?</span></span></p>",
      "unique_key": "Q9116270",
      "question_audio": null,
      "question_video": null,
      "map_id": 20730,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Glutamic acid to lysine</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbC disease is caused by the substitution of glutamic acid with lysine at the sixth position of the beta-globin chain. This change leads to the formation of HbC crystals, which can cause mild to moderate hemolytic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Valine to glutamic acid:</span></strong><span style=\"font-size:12.0pt\"> This substitution is the characteristic change for sickle cell anemia (HbS). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lysine to glutamic acid:</span></strong><span style=\"font-size:12.0pt\"> Swapping these two positively charged amino acids would likely have a minimal effect on hemoglobin function. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Glutamic acid to valine:</span></strong><span style=\"font-size:12.0pt\"> This substitution is also seen in HbS and leads to the polymerization of red blood cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbC disease is a milder form of hemoglobinopathy compared to sickle cell disease, but it is important to distinguish it based on the specific amino acid substitution.</span></span></span></p>",
      "correct_choice_id": 83039,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20771,
      "choices": [
        {
          "id": 83047,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbC disease </span></span></span></p>"
        },
        {
          "id": 83048,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbSC disease </span></span></span></p>"
        },
        {
          "id": 83049,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbD disease </span></span></span></p>"
        },
        {
          "id": 83050,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbDC disease</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 10-year-old child presents with severe anemia, jaundice, and splenomegaly. Their hemoglobin level is 5 g/dL. The peripheral blood smear shows numerous target cells and sickled red blood cells. Which of the following hemoglobinopathies is most likely?</span></span></p>",
      "unique_key": "Q3044424",
      "question_audio": null,
      "question_video": null,
      "map_id": 20732,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) HbDC disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbDC disease is a severe hemoglobinopathy that mimics sickle cell disease (HbSS), with severe anemia, vaso-occlusive crises, and organ damage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. HbC disease:</span></strong><span style=\"font-size:12.0pt\"> Usually mild anemia without severe complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. HbSC disease:</span></strong><span style=\"font-size:12.0pt\"> Typically less severe than HbSS, with a hemoglobin level usually &gt;10 g/dL.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. HbD disease:</span></strong><span style=\"font-size:12.0pt\"> Typically asymptomatic or mild anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbDC disease is a severe hemoglobinopathy that can present similarly to sickle cell disease (HbSS).</span></span></span></p>",
      "correct_choice_id": 83050,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20772,
      "choices": [
        {
          "id": 83051,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Autosomal dominant </span></span></span></p>"
        },
        {
          "id": 83052,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Autosomal recessive </span></span></span></p>"
        },
        {
          "id": 83053,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">X-linked dominant </span></span></span></p>"
        },
        {
          "id": 83054,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">X-linked recessive</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the MOST common inheritance pattern of G6PD deficiency?</span></span></p>",
      "unique_key": "Q4791916",
      "question_audio": null,
      "question_video": null,
      "map_id": 20733,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) X-linked recessive</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">G6PD deficiency is inherited in an X-linked recessive pattern. This means that the mutated gene is located on the X chromosome, and males (who have only one X chromosome) are more likely to be affected than females (who have two X chromosomes).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The X-linked recessive inheritance pattern of G6PD deficiency explains why it is more common in males and why females can be asymptomatic carriers.</span></span></span></p>",
      "correct_choice_id": 83054,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20782,
      "choices": [
        {
          "id": 83091,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Budd-Chiari syndrome </span></span></span></p>"
        },
        {
          "id": 83092,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Esophageal stricture </span></span></span></p>"
        },
        {
          "id": 83093,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Portal vein thrombosis </span></span></span></p>"
        },
        {
          "id": 83094,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gastric ulcer</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman with PNH treated with eculizumab develops recurrent abdominal pain and difficulty swallowing. Which of the following complications is MOST likely?</span></span></p>",
      "unique_key": "Q6561336",
      "question_audio": null,
      "question_video": null,
      "map_id": 20743,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Portal vein thrombosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thrombosis, especially in unusual locations like the portal vein, is a major complication of PNH. Abdominal pain and dysphagia can be symptoms of portal vein thrombosis.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Budd-Chiari syndrome:</span></strong><span style=\"font-size:12.0pt\"> This is a rare condition involving obstruction of hepatic veins, typically presenting with liver enlargement, abdominal pain, and ascites. While possible in PNH, it&#39;s less likely than portal vein thrombosis given the dysphagia (difficulty swallowing).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Esophageal stricture:</span></strong><span style=\"font-size:12.0pt\"> Strictures usually cause progressive dysphagia and are not typically associated with acute abdominal pain. While PNH can cause esophageal dysmotility, strictures are less common.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Gastric ulcer:</span></strong><span style=\"font-size:12.0pt\"> While abdominal pain is a possible symptom of gastric ulcers, they are not a common complication specifically associated with PNH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paroxysmal nocturnal hemoglobinuria (PNH) predisposes individuals to a hypercoagulable state. This means they are at higher risk for blood clots forming in unusual locations. Portal vein thrombosis is one such complication, and its presentation can include abdominal pain and difficulty swallowing. It&#39;s important for clinicians to maintain a high index of suspicion for thrombosis in PNH patients, even while on eculizumab therapy.</span></span></span></p>",
      "correct_choice_id": 83093,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20792,
      "choices": [
        {
          "id": 83131,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Microcytic anemia and normal methylmalonic acid (MMA) level </span></span></span></p>"
        },
        {
          "id": 83132,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macrocytic anemia and elevated MMA level </span></span></span></p>"
        },
        {
          "id": 83133,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Macrocytic anemia and normal MMA level </span></span></span></p>"
        },
        {
          "id": 83134,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Normocytic anemia and elevated homocysteine level</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old vegan presents with fatigue, pallor, and numbness and tingling in their hands and feet. Which of the following laboratory findings would be MOST consistent with the suspected diagnosis?</span></span></p>",
      "unique_key": "Q8122319",
      "question_audio": null,
      "question_video": null,
      "map_id": 20753,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Macrocytic anemia and elevated MMA level</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation (fatigue, pallor, neurological symptoms) and vegan diet strongly suggest vitamin B12 deficiency. Macrocytic anemia is a hallmark of B12 deficiency, and elevated MMA levels are specific for this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Microcytic anemia and normal methylmalonic acid (MMA) level:</span></strong><span style=\"font-size:12.0pt\"> Microcytic anemia is associated with iron deficiency, not B12 deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Macrocytic anemia and normal MMA level:</span></strong><span style=\"font-size:12.0pt\"> While macrocytic anemia is consistent with B12 deficiency, normal MMA levels would not be expected.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Normocytic anemia and elevated homocysteine level:</span></strong><span style=\"font-size:12.0pt\"> Normocytic anemia is not typical of B12 deficiency, and while homocysteine can be elevated in both B12 and folate deficiencies, it&#39;s not specific for B12.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 deficiency should be suspected in vegans presenting with neurological symptoms and macrocytic anemia. Elevated MMA levels are a specific marker for B12 deficiency.</span></span></span></p>",
      "correct_choice_id": 83132,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20793,
      "choices": [
        {
          "id": 83135,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Autoimmune destruction of blood cells </span></span></span></p>"
        },
        {
          "id": 83136,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Impaired DNA synthesis in hematopoietic stem cells </span></span></span></p>"
        },
        {
          "id": 83137,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bone marrow infiltration with malignant cells </span></span></span></p>"
        },
        {
          "id": 83138,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypersplenism</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with vitamin B12 deficiency is found to have pancytopenia (low counts of all blood cell types). Which of the following is the most likely mechanism for this finding?</span></span></p>",
      "unique_key": "Q3079981",
      "question_audio": null,
      "question_video": null,
      "map_id": 20754,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Impaired DNA synthesis in hematopoietic stem cells</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 is essential for DNA synthesis. Its deficiency impairs cell division and maturation in the bone marrow, leading to pancytopenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Autoimmune destruction of blood cells:</span></strong><span style=\"font-size:12.0pt\"> While some autoimmune conditions can cause pancytopenia, it&#39;s not the primary mechanism in vitamin B12 deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Bone marrow infiltration with malignant cells:</span></strong><span style=\"font-size:12.0pt\"> This would be more typical of leukemias or other malignancies, not vitamin B12 deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hypersplenism:</span></strong><span style=\"font-size:12.0pt\"> Hypersplenism can cause some degree of cytopenia, but it usually doesn&#39;t affect all cell lines equally, and it&#39;s not the primary cause in B12 deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 deficiency can cause pancytopenia due to impaired DNA synthesis in hematopoietic stem cells.</span></span></span></p>",
      "correct_choice_id": 83136,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20794,
      "choices": [
        {
          "id": 83139,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Oral cyanocobalamin 1000 mcg daily </span></span></span></p>"
        },
        {
          "id": 83140,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intramuscular (IM) hydroxocobalamin 1000 mcg every 3 months </span></span></span></p>"
        },
        {
          "id": 83141,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Intramuscular (IM) hydroxocobalamin 1000 mcg every 3-7 days for 6 doses, then every 3 months </span></span></span></p>"
        },
        {
          "id": 83142,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sublingual cyanocobalamin 1000 mcg daily</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old woman with pernicious anemia (PA) presents with severe anemia (hemoglobin 7 g/dL) and neurologic symptoms. Which of the following is the MOST appropriate initial treatment?</span></span></span></p>",
      "unique_key": "Q3554579",
      "question_audio": null,
      "question_video": null,
      "map_id": 20755,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Intramuscular (IM) hydroxocobalamin 1000 mcg every 3-7 days for 6 doses, then every 3 months</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Due to the patient&#39;s severe anemia and neurologic symptoms, prompt and efficient B12 repletion is crucial. IM hydroxocobalamin with initial frequent dosing is the most effective way to achieve this.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Oral cyanocobalamin 1000 mcg daily:</span></strong><span style=\"font-size:12.0pt\"> While high-dose oral cyanocobalamin can be used in some cases, it is less efficient than IM injections, especially when rapid repletion is needed due to severe anemia or neurological symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Intramuscular (IM) hydroxocobalamin 1000 mcg every 3 months:</span></strong><span style=\"font-size:12.0pt\"> This is a typical maintenance dose, but the initial treatment for severe deficiency requires more frequent dosing to rapidly correct the deficit.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sublingual cyanocobalamin 1000 mcg daily:</span></strong><span style=\"font-size:12.0pt\"> Sublingual absorption of B12 is less reliable and may not be sufficient for a patient with severe anemia and neurological symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The preferred initial treatment for severe B12 deficiency with neurological symptoms is intramuscular hydroxocobalamin given every 3-7 days for 6 doses, followed by maintenance therapy every 3 months.</span></span></span></p>",
      "correct_choice_id": 83141,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20795,
      "choices": [
        {
          "id": 83143,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspirin </span></span></span></p>"
        },
        {
          "id": 83144,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
        },
        {
          "id": 83145,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate </span></span></span></p>"
        },
        {
          "id": 83146,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Atorvastatin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following medications is MOST likely to interfere with folate metabolism and potentially lead to folate deficiency?</span></span></p>",
      "unique_key": "Q2609539",
      "question_audio": null,
      "question_video": null,
      "map_id": 20756,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Methotrexate</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methotrexate is a dihydrofolate reductase inhibitor, interfering with folate metabolism and leading to functional folate deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Aspirin:</span></strong><span style=\"font-size:12.0pt\"> While aspirin can cause some minor interference with folate absorption at very high doses, it&#39;s not a major contributor to folate deficiency at typical doses.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Metformin:</span></strong><span style=\"font-size:12.0pt\"> Metformin primarily affects glucose metabolism and doesn&#39;t have a direct impact on folate metabolism. However, long-term metformin use has been associated with mild decreases in vitamin B12 levels, which can sometimes be confused with folate deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Atorvastatin:</span></strong><span style=\"font-size:12.0pt\"> Atorvastatin is a cholesterol-lowering medication (statin) and does not interfere with folate metabolism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While all medications should be reviewed when a patient presents with folate deficiency, methotrexate stands out as the most likely culprit due to its direct inhibitory effect on dihydrofolate reductase, a key enzyme in folate metabolism.</span></span></span></p>",
      "correct_choice_id": 83145,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20780,
      "choices": [
        {
          "id": 83083,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Autoimmune hemolytic anemia </span></span></span></p>"
        },
        {
          "id": 83084,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glucose-6-phosphate dehydrogenase (G6PD) deficiency </span></span></span></p>"
        },
        {
          "id": 83085,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Paroxysmal nocturnal hemoglobinuria (PNH) </span></span></span></p>"
        },
        {
          "id": 83086,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sickle cell disease</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man presents with fatigue, abdominal pain, and dark urine, especially in the morning. Laboratory tests reveal hemoglobinuria and decreased levels of CD55 and CD59 on red blood cells. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q1475827",
      "question_audio": null,
      "question_video": null,
      "map_id": 20741,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Paroxysmal nocturnal hemoglobinuria (PNH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The classic triad of symptoms (fatigue, abdominal pain, and dark urine), along with decreased CD55 and CD59 levels on red blood cells, are characteristic of PNH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Autoimmune hemolytic anemia:</span></strong><span style=\"font-size:12.0pt\"> While it can present with anemia and hemolysis, it typically does not cause hemoglobinuria or have decreased CD55/CD59 levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glucose-6-phosphate dehydrogenase (G6PD) deficiency:</span></strong><span style=\"font-size:12.0pt\"> This usually presents with episodic hemolysis triggered by oxidative stress, not specifically at night.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sickle cell disease:</span></strong><span style=\"font-size:12.0pt\"> This is a genetic hemoglobinopathy with distinct clinical and laboratory findings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PNH is a rare acquired hemolytic anemia characterized by intravascular hemolysis, often more pronounced at night, and decreased CD55 and CD59 levels on blood cells.</span></span></span></p>",
      "correct_choice_id": 83085,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20763,
      "choices": [
        {
          "id": 83015,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Predominant HbA peak with a small HbS peak </span></span></span></p>"
        },
        {
          "id": 83016,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Predominant HbS peak with a small HbA peak </span></span></span></p>"
        },
        {
          "id": 83017,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Absence of HbA peak, predominant HbF peak </span></span></span></p>"
        },
        {
          "id": 83018,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Predominant HbA peak with elevated HbA2 peak</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following hemoglobin electrophoresis patterns is consistent with sickle cell trait?</span></span></p>",
      "unique_key": "Q3296713",
      "question_audio": null,
      "question_video": null,
      "map_id": 20724,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Predominant HbA peak with a small HbS peak</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Individuals with sickle cell trait have one normal beta-globin gene (producing HbA) and one mutated gene (producing HbS), resulting in a predominant HbA peak with a smaller HbS peak on electrophoresis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Predominant HbS peak with a small HbA peak:</span></strong><span style=\"font-size:12.0pt\"> This pattern is characteristic of sickle cell disease (SCD), not sickle cell trait. In SCD, both beta-globin genes are mutated, resulting in primarily HbS production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Absence of HbA peak, predominant HbF peak:</span></strong><span style=\"font-size:12.0pt\"> This pattern can be seen in certain conditions like beta-thalassemia major or hereditary persistence of fetal hemoglobin (HPFH). It is not consistent with sickle cell trait.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Predominant HbA peak with elevated HbA2 peak:</span></strong><span style=\"font-size:12.0pt\"> This pattern is suggestive of beta-thalassemia trait. While both beta-thalassemia trait and sickle cell trait can cause mild anemia, their Hb electrophoresis patterns differ.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Hb electrophoresis pattern in sickle cell trait differs from that of sickle cell disease, which shows a predominant HbS peak.</span></span></span></p>",
      "correct_choice_id": 83015,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20765,
      "choices": [
        {
          "id": 83023,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Reduced frequency of vaso-occlusive crises </span></span></span></p>"
        },
        {
          "id": 83024,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased fetal hemoglobin (HbF) levels </span></span></span></p>"
        },
        {
          "id": 83025,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased risk of acute chest syndrome </span></span></span></p>"
        },
        {
          "id": 83026,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased risk of infection</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a potential benefit of hydroxyurea therapy in sickle cell disease?</span></span></p>",
      "unique_key": "Q5068574",
      "question_audio": null,
      "question_video": null,
      "map_id": 20726,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Increased risk of infection</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hydroxyurea can actually <em>reduce</em> the risk of infection in sickle cell disease by decreasing the frequency of vaso-occlusive events and improving overall health.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hydroxyurea offers multiple benefits in sickle cell disease, including reduced complications and improved quality of life.</span></span></span></p>",
      "correct_choice_id": 83026,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20766,
      "choices": [
        {
          "id": 83027,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increasing fetal hemoglobin (HbF) levels </span></span></span></p>"
        },
        {
          "id": 83028,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreasing red blood cell sickling </span></span></span></p>"
        },
        {
          "id": 83029,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibiting platelet aggregation </span></span></span></p>"
        },
        {
          "id": 83030,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blocking adhesive interactions between sickle cells and endothelial cells</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old patient with sickle cell disease (SCD) and a history of frequent vaso-occlusive crises is being considered for treatment with crizanlizumab, a monoclonal antibody that targets P-selectin. What is the PRIMARY mechanism of action of crizanlizumab in preventing vaso-occlusive crises in SCD?</span></span></p>",
      "unique_key": "Q7522689",
      "question_audio": null,
      "question_video": null,
      "map_id": 20727,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Blocking adhesive interactions between sickle cells and endothelial cells</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Crizanlizumab, a P-selectin inhibitor, works by preventing the adhesion of sickle cells to the endothelium, thereby reducing the risk of vaso-occlusion and subsequent painful crises.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increasing fetal hemoglobin (HbF) levels:</span></strong><span style=\"font-size:12.0pt\"> Hydroxyurea, not crizanlizumab, is the primary medication used to increase HbF levels in sickle cell disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreasing red blood cell sickling:</span></strong><span style=\"font-size:12.0pt\"> While reducing adhesion can indirectly help prevent sickling, crizanlizumab&#39;s primary mechanism is not directly targeting the sickling process itself.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibiting platelet aggregation:</span></strong><span style=\"font-size:12.0pt\"> While platelets play a role in vaso-occlusion, crizanlizumab&#39;s primary target is P-selectin on endothelial cells, not platelets.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong><span style=\"font-size:12.0pt\"> </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">P-selectin blockade is a novel therapeutic approach in SCD that targets the adhesive interactions involved in vaso-occlusion.</span></span></span></p>",
      "correct_choice_id": 83030,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20767,
      "choices": [
        {
          "id": 83031,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbC only</span></span></span></p>"
        },
        {
          "id": 83032,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA and HbC</span></span></span></p>"
        },
        {
          "id": 83033,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA and HbS</span></span></span></p>"
        },
        {
          "id": 83034,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbS and HbC</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An&nbsp;11-year-old&nbsp;boy is brought to the physician by his mother because of worsening&nbsp;fatigue. His mother reports that he seems to have trouble keeping up with his older brothers when playing outside. Physical examination shows&nbsp;conjunctival pallor. A&nbsp;hemoglobin electrophoresis&nbsp;is performed. This patient&#39;s results are shown in comparison to those of a patient with known sickle cell anemia and a child with normal hemoglobin. Based on this electrophoresis, which of the following types of hemoglobin are dominant in this patient&#39;s blood?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/31/whatsapp-image-2024-07-31-at-50300-pm.jpeg\" style=\"height:484px; width:200px\" /></p>",
      "unique_key": "Q5759883",
      "question_audio": null,
      "question_video": null,
      "map_id": 20728,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) HbS and HbC</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HbA&nbsp;(&alpha;<sub>2</sub>&beta;<sub>2</sub>), which is the predominant form of&nbsp;hemoglobin&nbsp;by the age of 6 months, migrates farther than&nbsp;HbS, which is the predominant&nbsp;hemoglobin&nbsp;of patients with&nbsp;sickle cell disease. This is because&nbsp;HbS&nbsp;contains a neutral&nbsp;valine&nbsp;residue at&nbsp;position 6 within the beta subunit in place of the normal, negatively charged&nbsp;glutamic acid&nbsp;residue.&nbsp;HbS, in turn, migrates farther than&nbsp;HbC&nbsp;because&nbsp;HbC&nbsp;contains a positively charged&nbsp;lysine&nbsp;residue in the same position. The thin band between&nbsp;HbS&nbsp;and&nbsp;HbA&nbsp;in the&nbsp;sickle cell&nbsp;patient&#39;s sample is&nbsp;HbF&nbsp;(&alpha;<sub>2</sub>&gamma;<sub>2</sub>), which is slightly less negatively charged than&nbsp;HbA&nbsp;but more negatively charged than&nbsp;HbS.&nbsp;HbF&nbsp;is normally present in negligible quantities by early childhood but patients with&nbsp;sickle cell disease&nbsp;often have increased levels of&nbsp;HbF. This patient&#39;s&nbsp;hemoglobin electrophoresis&nbsp;shows one band at the position of the&nbsp;HbS&nbsp;band and the other at a position closer to the cathode than&nbsp;HbS. Therefore, this patient has&nbsp;HbSC disease.&nbsp;HbSC&nbsp;patients have milder symptoms than those with&nbsp;homozygous&nbsp;sickle cell anemia&nbsp;(HbSS).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. HbC only:</span></strong><span style=\"font-size:12.0pt\"> Individuals&nbsp;homozygous&nbsp;for&nbsp;HbC&nbsp;have&nbsp;hemoglobin C disease, which typically manifests with mild&nbsp;anemia. The electrophoresis pattern of a patient with&nbsp;HbC disease&nbsp;would show a single thicker band that migrates even less than&nbsp;HbS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. HbA and HbC:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Individuals with the&nbsp;hemoglobin C&nbsp;trait would have both&nbsp;HbA&nbsp;and&nbsp;HbC&nbsp;in their blood.&nbsp;Hemoglobin electrophoresis&nbsp;of this patient shows&nbsp;HbC&nbsp;but not&nbsp;HbA. Moreover,&nbsp;hemoglobin C&nbsp;trait is usually an asymptomatic carrier state, unlike this patient with fatigue.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. HbA and HbS:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Individuals&nbsp;heterozygous&nbsp;for the&nbsp;sickle cell trait&nbsp;would have both&nbsp;HbA&nbsp;and&nbsp;HbS&nbsp;in their blood.&nbsp;Hemoglobin electrophoresis&nbsp;of this patient shows&nbsp;HbS&nbsp;but not&nbsp;HbA. Moreover, individuals&nbsp;heterozygous&nbsp;for the&nbsp;sickle cell trait&nbsp;are usually asymptomatic, unlike this patient with fatigue.</span></span></span></p>",
      "correct_choice_id": 83034,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20773,
      "choices": [
        {
          "id": 83055,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acetaminophen </span></span></span></p>"
        },
        {
          "id": 83056,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Penicillin </span></span></span></p>"
        },
        {
          "id": 83057,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ciprofloxacin </span></span></span></p>"
        },
        {
          "id": 83058,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nitrofurantoin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman with G6PD deficiency presents with jaundice and fatigue. Her laboratory results show hemoglobin of 8 g/dL and elevated indirect bilirubin. Which of the following medications would be MOST likely to trigger this hemolytic episode?</span></span></p>",
      "unique_key": "Q1995812",
      "question_audio": null,
      "question_video": null,
      "map_id": 20734,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Nitrofurantoin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nitrofurantoin is a known oxidant stressor that can trigger hemolysis in individuals with G6PD deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><span style=\"font-size:12.0pt\">&nbsp;<strong>Acetaminophen</strong>:&nbsp;</span><span style=\"font-size:12.0pt\">Acetaminophen is not a common trigger of G6PD deficiency-related hemolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Penicillin</strong>:&nbsp;</span><span style=\"font-size:12.0pt\">Penicillin is generally safe in G6PD deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Ciprofloxacin</strong>:&nbsp;</span><span style=\"font-size:12.0pt\">Ciprofloxacin is not a common trigger of G6PD deficiency-related hemolysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It is crucial to avoid medications that can trigger hemolysis in patients with G6PD deficiency.</span></span></span></p>",
      "correct_choice_id": 83058,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20775,
      "choices": [
        {
          "id": 83063,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bone marrow biopsy </span></span></span></p>"
        },
        {
          "id": 83064,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hemoglobin electrophoresis </span></span></span></p>"
        },
        {
          "id": 83065,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Osmotic fragility test (OFT) </span></span></span></p>"
        },
        {
          "id": 83066,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Direct antiglobulin test </span><span style=\"font-size:12.0pt\">(DAT)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman with a history of hereditary spherocytosis presents with fatigue and pallor. Her laboratory tests reveal anemia with an increased mean corpuscular hemoglobin concentration (MCHC) and an increased red cell distribution width (RDW). Which of the following tests would be MOST helpful in confirming the diagnosis?</span></span></p>",
      "unique_key": "Q1336516",
      "question_audio": null,
      "question_video": null,
      "map_id": 20736,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Osmotic fragility test (OFT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The OFT is a classic diagnostic test for hereditary spherocytosis, as spherocytes are more susceptible to osmotic stress and lyse at higher salt concentrations than normal red blood cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Bone marrow biopsy</span></strong><span style=\"font-size:12.0pt\"> is not typically needed for the diagnosis of HS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. &nbsp;Hemoglobin electrophoresis</span></strong><span style=\"font-size:12.0pt\"> is used to diagnose hemoglobinopathies, not HS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Direct antiglobulin test (DAT)</span></strong><span style=\"font-size:12.0pt\"> is used to diagnose autoimmune hemolytic anemia, not HS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The osmotic fragility test is a useful tool for diagnosing hereditary spherocytosis.</span></span></span></p>",
      "correct_choice_id": 83065,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20776,
      "choices": [
        {
          "id": 83067,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Folate supplementation </span></span></span></p>"
        },
        {
          "id": 83068,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Blood transfusions </span></span></span></p>"
        },
        {
          "id": 83069,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Splenectomy </span></span></span></p>"
        },
        {
          "id": 83070,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iron chelation therapy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most definitive treatment for hereditary spherocytosis?</span></span></p>",
      "unique_key": "Q5037882",
      "question_audio": null,
      "question_video": null,
      "map_id": 20738,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Splenectomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Splenectomy is the most definitive treatment for hereditary spherocytosis, as it removes the primary site of red blood cell destruction. However, it is usually reserved for patients with moderate to severe anemia or complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Folate supplementation&nbsp;</span></strong><span style=\"font-size:12.0pt\">and <strong>Option B. Blood transfusions</strong> are supportive measures but do not cure the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Iron chelation therapy</span></strong><span style=\"font-size:12.0pt\"> is used to treat iron overload, not hereditary spherocytosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Splenectomy is the definitive treatment for hereditary spherocytosis but is typically reserved for patients with moderate to severe disease.</span></span></span></p>",
      "correct_choice_id": 83069,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20778,
      "choices": [
        {
          "id": 83075,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased cholesterol secretion </span></span></span></p>"
        },
        {
          "id": 83076,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased bile acid synthesis </span></span></span></p>"
        },
        {
          "id": 83077,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased pigment excretion </span></span></span></p>"
        },
        {
          "id": 83078,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased gallbladder motility</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 15-year-old girl with hereditary spherocytosis presents with right upper quadrant pain. Ultrasound reveals gallstones. Which of the following is the most likely mechanism of gallstone formation in this patient?</span></span></span></p>",
      "unique_key": "Q1256244",
      "question_audio": null,
      "question_video": null,
      "map_id": 20739,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Increased pigment excretion</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Chronic hemolysis in hereditary spherocytosis leads to increased bilirubin production and excretion, which can promote the formation of pigment gallstones.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increased cholesterol secretion:</span></strong><span style=\"font-size:12.0pt\"> While cholesterol is a major component of gallstones, increased secretion is not the primary culprit in HS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreased bile acid synthesis:</span></strong><span style=\"font-size:12.0pt\"> Decreased bile acid synthesis can promote cholesterol gallstones, but it is not a major factor in pigment gallstone formation seen in HS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Decreased gallbladder motility:</span></strong><span style=\"font-size:12.0pt\"> Decreased gallbladder motility can contribute to gallstone formation, but it is not the most specific or common finding in HS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gallstones are a common complication of hereditary spherocytosis due to increased pigment excretion.</span></span></span></p>",
      "correct_choice_id": 83077,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20787,
      "choices": [
        {
          "id": 83111,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Peripheral blood smear </span></span></span></p>"
        },
        {
          "id": 83112,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ham&#39;s test </span></span></span></p>"
        },
        {
          "id": 83113,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sucrose hemolysis test </span></span></span></p>"
        },
        {
          "id": 83114,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-sensitivity flow cytometry</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following tests is considered the GOLD STANDARD for diagnosing paroxysmal nocturnal hemoglobinuria (PNH)?</span></span></p>",
      "unique_key": "Q6716631",
      "question_audio": null,
      "question_video": null,
      "map_id": 20748,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) High-sensitivity flow cytometry</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-sensitivity flow cytometry is the most sensitive and specific test for PNH, allowing for the detection of even small populations of GPI-deficient cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Peripheral blood smear:</span></strong><span style=\"font-size:12.0pt\"> While it may show signs of hemolysis (like fragmented red blood cells or spherocytes), it cannot definitively diagnose PNH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ham&#39;s test:</span></strong><span style=\"font-size:12.0pt\"> This is an older, less specific test for PNH that is rarely used today due to its lower sensitivity and potential for false positives.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Sucrose hemolysis test:</span></strong><span style=\"font-size:12.0pt\"> This test is also less sensitive and specific than flow cytometry.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">High-sensitivity flow cytometry is the gold standard for diagnosing PNH due to its ability to directly detect the absence of GPI-anchored proteins on red and white blood cells.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Older tests like the Ham&#39;s test and sucrose hemolysis test are less reliable and have been largely replaced by flow cytometry.</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 83114,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20788,
      "choices": [
        {
          "id": 83115,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisone </span></span></span></p>"
        },
        {
          "id": 83116,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ravulizumab </span></span></span></p>"
        },
        {
          "id": 83117,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rituximab </span></span></span></p>"
        },
        {
          "id": 83118,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cyclosporine</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH)?</span></span></p>",
      "unique_key": "Q3946276",
      "question_audio": null,
      "question_video": null,
      "map_id": 20749,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Ravulizumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eculizumab and ravulizumab are monoclonal antibodies that inhibit complement activation, the underlying mechanism of hemolysis in PNH. They are the first-line treatment options.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Prednisone:</span></strong><span style=\"font-size:12.0pt\"> While corticosteroids like prednisone may be used in some cases of autoimmune hemolytic anemia, they are not the first-line treatment for PNH. They are less effective than eculizumab or ravulizumab at controlling hemolysis and thrombosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Rituximab:</span></strong><span style=\"font-size:12.0pt\"> Rituximab is a monoclonal antibody that targets B cells. While it can be used in some autoimmune disorders, it is not indicated for PNH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Cyclosporine:</span></strong><span style=\"font-size:12.0pt\"> Cyclosporine is an immunosuppressant used in various conditions, including organ transplantation and some autoimmune disorders. It has no direct effect on the complement system, which is the primary driver of PNH, and thus is not used in its treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Eculizumab and ravulizumab have revolutionized the treatment of PNH by significantly reducing hemolysis, thrombosis risk, and improving quality of life.</span></span></span></p>",
      "correct_choice_id": 83116,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20789,
      "choices": [
        {
          "id": 83119,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute myeloid leukemia (AML) </span></span></span></p>"
        },
        {
          "id": 83120,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Myelodysplastic syndrome (MDS) </span></span></span></p>"
        },
        {
          "id": 83121,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aplastic anemia (AA) </span></span></span></p>"
        },
        {
          "id": 83122,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vitamin B12 deficiency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old male presents with fatigue, recurrent infections, and easy bruising. Laboratory findings reveal pancytopenia, and a bone marrow biopsy shows hypocellular marrow replaced with fat. Which of the following is the MOST likely diagnosis?</span></span></p>",
      "unique_key": "Q6871837",
      "question_audio": null,
      "question_video": null,
      "map_id": 20750,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. C) Aplastic anemia (AA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The classic triad of pancytopenia, hypocellular (fatty) marrow, and the absence of abnormal cells rules out leukemia and MDS. Vitamin B12 deficiency usually causes macrocytic anemia, not pancytopenia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Acute myeloid leukemia (AML):</span></strong><span style=\"font-size:12.0pt\"> AML would typically present with blasts (immature white blood cells) in the peripheral blood and a hypercellular bone marrow.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Myelodysplastic syndrome (MDS):</span></strong><span style=\"font-size:12.0pt\"> MDS is characterized by dysplastic changes in the bone marrow and peripheral blood cells, which are not present in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vitamin B12 deficiency:</span></strong><span style=\"font-size:12.0pt\"> While vitamin B12 deficiency can cause pancytopenia, it usually manifests with a macrocytic anemia (large red blood cells) and megaloblastic changes in the bone marrow.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aplastic anemia is a diagnosis of exclusion, characterized by pancytopenia and hypocellular bone marrow.</span></span></span></p>",
      "correct_choice_id": 83121,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20790,
      "choices": [
        {
          "id": 83123,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased CD34+ cells </span></span></span></p>"
        },
        {
          "id": 83124,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Decreased or absent CD34+ cells </span></span></span></p>"
        },
        {
          "id": 83125,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increased blasts </span></span></span></p>"
        },
        {
          "id": 83126,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Monoclonal B-cell population</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flow cytometry in a patient with suspected aplastic anemia is most likely to reveal:</span></span></span></p>",
      "unique_key": "Q3529497",
      "question_audio": null,
      "question_video": null,
      "map_id": 20751,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Decreased or absent CD34+ cells</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CD34+ cells are hematopoietic stem and progenitor cells. Their decrease or absence reflects the bone marrow failure in aplastic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Increased CD34+ cells:</span></strong><span style=\"font-size:12.0pt\"> This would be seen in conditions with increased hematopoietic activity, such as recovery from chemotherapy or certain leukemias. It&#39;s not expected in aplastic anemia where the bone marrow is failing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Increased blasts:</span></strong><span style=\"font-size:12.0pt\"> Increased blasts (immature blood cells) would suggest acute leukemia or myelodysplastic syndrome (MDS), not aplastic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Monoclonal B-cell population:</span></strong><span style=\"font-size:12.0pt\"> This finding would be more indicative of a lymphoproliferative disorder, such as chronic lymphocytic leukemia (CLL) or lymphoma, rather than aplastic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flow cytometry can help confirm the diagnosis of aplastic anemia by demonstrating a lack of CD34+ cells.</span></span></span></p>",
      "correct_choice_id": 83124,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20791,
      "choices": [
        {
          "id": 83127,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Immunosuppressive therapy (IST) </span></span></span></p>"
        },
        {
          "id": 83128,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Allogeneic hematopoietic stem cell transplant (HSCT)</span></span></span></p>"
        },
        {
          "id": 83129,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Supportive care with blood transfusions and antibiotics </span></span></span></p>"
        },
        {
          "id": 83130,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Androgens</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 18-year-old male presents with severe fatigue, recurrent infections, and easy bruising. Laboratory investigations reveal pancytopenia, and a bone marrow biopsy shows markedly hypocellular marrow. He has an HLA-matched sibling. Which of the following is the MOST appropriate first-line treatment for this patient?</span></span></p>",
      "unique_key": "Q8334916",
      "question_audio": null,
      "question_video": null,
      "map_id": 20752,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Allogeneic hematopoietic stem cell transplant (HSCT)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient&#39;s presentation and laboratory findings are consistent with severe aplastic anemia. For young patients with severe aplastic anemia and an HLA-matched sibling donor, allogeneic hematopoietic stem cell transplant (HSCT) is the preferred first-line treatment, offering the potential for cure by replacing the damaged bone marrow with healthy stem cells from the donor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Immunosuppressive therapy (IST):&nbsp;</span></strong><span style=\"font-size:12.0pt\">While IST is an effective treatment for aplastic anemia, it&#39;s typically the first-line choice for patients who <em>don&#39;t</em> have a matched sibling donor or are older. It aims to suppress the immune system, which is often attacking the bone marrow in acquired aplastic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Supportive care with blood transfusions and antibiotics:</span></strong><span style=\"font-size:12.0pt\"> This is crucial for managing the symptoms and complications of aplastic anemia (e.g., anemia, infection). However, it is not a curative treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Androgens:</span></strong><span style=\"font-size:12.0pt\"> Androgens (male sex hormones) can sometimes stimulate the bone marrow, but their efficacy is limited and not usually the first-line choice in severe aplastic anemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The best treatment approach for aplastic anemia depends on the patient&#39;s age, severity of the disease, and availability of a matched sibling donor. For young patients with severe aplastic anemia and a matched sibling donor, allogeneic HSCT offers the best chance for a cure.</span></span></span></p>",
      "correct_choice_id": 83128,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}